Recent evidence suggests that kinase activity of BCR-ABL oncoprotein in CML stem cells is inhibited by TKI treatment without affecting CML stem cell survival [27, 28]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.